Sustained, high transgene expression in liver with plasmid vectors using optimized promoter-enhancer combinations.
about
Generation of a tumor- and tissue-specific episomal non-viral vector system.Hydrodynamic Gene Delivery of CC Chemokine Binding Fc Fusion Proteins to Target Acute Vascular Inflammation In Vivo.Non-viral therapeutic approaches to ocular diseases: An overview and future directionsSystemic TNFα gene therapy synergizes with liposomal doxorubicine in the treatment of metastatic cancer.A review of therapeutic prospects of non-viral gene therapy in the retinal pigment epitheliumVaccination with a piggyBac plasmid with transgene integration potential leads to sustained antigen expression and CD8(+) T cell responsesNucleic-acid based gene therapeutics: delivery challenges and modular design of nonviral gene carriers and expression cassettes to overcome intracellular barriers for sustained targeted expression.Controlling the kinetics of interferon transgene expression for improved gene therapy.Identifying and engineering promoters for high level and sustainable therapeutic recombinant protein production in cultured mammalian cells.In vitro exploration of a myeloid-derived suppressor cell line as vehicle for cancer gene therapy.Host-Guest-Mediated DNA Templation of Polycationic Supramolecules for Hierarchical Nanocondensation and the Delivery of Gene Material.De-targeting by miR-143 decreases unwanted transgene expression in non-tumorigenic cells.Transient Hepatic Overexpression of Insulin-Like Growth Factor 2 Induces Free Cholesterol and Lipid Droplet Formation.Impact of different promoters, promoter mutation, and an enhancer on recombinant protein expression in CHO cells.Non-viral gene therapy that targets motor neurons in vivo.Promoter and Terminator Discovery and Engineering.Translational Advances of Hydrofection by Hydrodynamic Injection.
P2860
Q34756391-D07FE249-78AA-4927-9CCE-067762DD9C44Q36333599-D6FBADD4-1E4C-4AE7-A8A2-43E2D4B5BB5AQ36425890-FF830CE2-1317-4D04-A847-CD995901B855Q36673686-397A4428-ADD9-4857-833C-F0BA1352ED2EQ37091380-B927CE68-424E-427E-9D7B-C092ABE2A99AQ37680063-C699485E-5362-4A87-8BEB-C0E253831F34Q37981217-FDE91592-2746-4B97-865A-C1A669C98616Q38044941-C3E7688B-A9BF-4FA6-8AA6-28890755B03AQ38204917-13C8E99F-784C-4812-9EF1-0D616251FE29Q38730553-1131A268-54C4-4A92-B6B4-D79762DA66A1Q38851910-3ECBAAF3-1157-4B47-9BD2-5178642B1C11Q39134517-1EDF6842-617C-41CD-963D-AE62CCB4926DQ40587873-96F4C435-00AA-4102-AEAA-6AA45FC6D4A6Q41621451-66A0CA8E-CBB4-4C16-921E-EA6DC8BA0DC2Q41760723-827A2E5C-0E29-43A6-AB71-2D45FF087C32Q51299593-0FE280E6-D461-49A1-BD5D-231A7E8C643CQ51730568-D73DA6B0-D4F0-4895-A018-78F963D439AB
P2860
Sustained, high transgene expression in liver with plasmid vectors using optimized promoter-enhancer combinations.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Sustained, high transgene expr ...... romoter-enhancer combinations.
@en
Sustained, high transgene expr ...... romoter-enhancer combinations.
@nl
type
label
Sustained, high transgene expr ...... romoter-enhancer combinations.
@en
Sustained, high transgene expr ...... romoter-enhancer combinations.
@nl
prefLabel
Sustained, high transgene expr ...... romoter-enhancer combinations.
@en
Sustained, high transgene expr ...... romoter-enhancer combinations.
@nl
P2093
P2860
P356
P1476
Sustained, high transgene expr ...... romoter-enhancer combinations.
@en
P2093
Manfred Ogris
Martin Schleef
Rudolf Haase
Terese Magnusson
P2860
P304
P356
10.1002/JGM.1585
P50
P577
2011-07-01T00:00:00Z